A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by
the exposure of non-tumor cells to cytotoxic agents. Use of molecular targeted drugs, such …

Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an
effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been …

Purpose: An anti-HER2 antibody–drug conjugate with a novel topoisomerase I inhibitor, DS-
8201a, was generated as a new antitumor drug candidate, and its preclinical pharmacologic …

Background Antibody–drug conjugates have emerged as a powerful strategy in cancer
therapy and combine the ability of monoclonal antibodies to specifically target tumour cells …

Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

Glioblastoma is the most common primary malignant brain tumour. Survival is poor and
improved treatment options are urgently needed. Although immunotherapies have emerged …

Importance Molecular aberrations in the phosphatidylinositol-3-kinase (PI3K) pathway drive
tumorigenesis. Frequently co-occurring alterations in hormone receptors and/or human …

T cell–directed cancer immunotherapy often fails to generate lasting tumor control.
Harnessing additional effectors of the immune response against tumors may strengthen the …

Lung cancer is the leading cause of cancer mortality worldwide. Comprehensive genomic
profiling of lung cancers revealed their genetic heterogeneity and complexity and identified …

Precision medicine has exploited next-generation sequencing (NGS) and gene/immune-
targeted drug deployment to transform the outlook for several lethal cancers. For instance …